BioNano Genomics (NASDAQ:BNGO) Rating Reiterated by Maxim Group

Maxim Group reiterated their buy rating on shares of BioNano Genomics (NASDAQ:BNGO) in a report published on Friday, AnalystRatings.com reports. Maxim Group currently has a $3.00 price target on the stock.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

BNGO has been the subject of several other research reports. ValuEngine raised shares of BioNano Genomics from a hold rating to a buy rating in a research report on Thursday, August 1st. Zacks Investment Research downgraded shares of BioNano Genomics from a hold rating to a sell rating in a research report on Monday, September 23rd.

Shares of BNGO traded down $0.14 during mid-day trading on Friday, reaching $0.88. The company had a trading volume of 6,094,800 shares, compared to its average volume of 1,340,145. BioNano Genomics has a fifty-two week low of $0.50 and a fifty-two week high of $8.00. The stock has a market cap of $16.94 million, a price-to-earnings ratio of -0.34 and a beta of 1.06. The company has a current ratio of 3.17, a quick ratio of 2.77 and a debt-to-equity ratio of 3.13. The firm has a fifty day simple moving average of $0.92 and a 200-day simple moving average of $2.14.

BioNano Genomics (NASDAQ:BNGO) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.57) by ($0.14). The firm had revenue of $2.18 million for the quarter, compared to analysts’ expectations of $2.56 million. BioNano Genomics had a negative return on equity of 347.02% and a negative net margin of 247.03%. As a group, equities analysts predict that BioNano Genomics will post -2.55 EPS for the current fiscal year.

About BioNano Genomics

Bionano Genomics, Inc operates as a life sciences instrumentation company in the genome analysis space. The company develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets, and to streamline the study of changes in chromosomes, which is known as cytogenetics.

Featured Story: Market Perform

Leave a Reply

Your email address will not be published. Required fields are marked *

*